AU2014337064B2 - Bromodomain inhibitors - Google Patents

Bromodomain inhibitors Download PDF

Info

Publication number
AU2014337064B2
AU2014337064B2 AU2014337064A AU2014337064A AU2014337064B2 AU 2014337064 B2 AU2014337064 B2 AU 2014337064B2 AU 2014337064 A AU2014337064 A AU 2014337064A AU 2014337064 A AU2014337064 A AU 2014337064A AU 2014337064 B2 AU2014337064 B2 AU 2014337064B2
Authority
AU
Australia
Prior art keywords
compound
formula
embodiment provides
another embodiment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014337064A
Other languages
English (en)
Other versions
AU2014337064A1 (en
Inventor
Michael John Bennett
Juan Manuel Betancort
Amogh Boloor
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of AU2014337064A1 publication Critical patent/AU2014337064A1/en
Priority to AU2019201352A priority Critical patent/AU2019201352B2/en
Application granted granted Critical
Publication of AU2014337064B2 publication Critical patent/AU2014337064B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Magnetic Treatment Devices (AREA)
  • Finger-Pressure Massage (AREA)
AU2014337064A 2013-10-18 2014-10-17 Bromodomain inhibitors Active AU2014337064B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201352A AU2019201352B2 (en) 2013-10-18 2019-02-26 Bromodomain inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361893133P 2013-10-18 2013-10-18
US61/893,133 2013-10-18
US201461931467P 2014-01-24 2014-01-24
US61/931,467 2014-01-24
PCT/US2014/061261 WO2015058160A1 (en) 2013-10-18 2014-10-17 Bromodomain inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201352A Division AU2019201352B2 (en) 2013-10-18 2019-02-26 Bromodomain inhibitors

Publications (2)

Publication Number Publication Date
AU2014337064A1 AU2014337064A1 (en) 2016-05-05
AU2014337064B2 true AU2014337064B2 (en) 2019-03-14

Family

ID=52826700

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014337064A Active AU2014337064B2 (en) 2013-10-18 2014-10-17 Bromodomain inhibitors
AU2019201352A Active AU2019201352B2 (en) 2013-10-18 2019-02-26 Bromodomain inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201352A Active AU2019201352B2 (en) 2013-10-18 2019-02-26 Bromodomain inhibitors

Country Status (32)

Country Link
US (8) US9034900B2 (enExample)
EP (4) EP4134364B1 (enExample)
JP (2) JP6445574B2 (enExample)
KR (1) KR102311573B1 (enExample)
CN (2) CN108558889B (enExample)
AU (2) AU2014337064B2 (enExample)
BR (1) BR112016008593B1 (enExample)
CA (2) CA3148196A1 (enExample)
CL (2) CL2016000925A1 (enExample)
CR (1) CR20160229A (enExample)
CY (2) CY1122734T1 (enExample)
DK (3) DK3057586T3 (enExample)
EA (1) EA035727B1 (enExample)
ES (3) ES2775217T3 (enExample)
FI (1) FI3640241T3 (enExample)
HR (3) HRP20221389T1 (enExample)
HU (2) HUE048371T2 (enExample)
IL (2) IL245074B (enExample)
LT (3) LT3057586T (enExample)
MX (2) MX371386B (enExample)
NI (1) NI201600056A (enExample)
PE (2) PE20161065A1 (enExample)
PH (1) PH12016500722A1 (enExample)
PL (3) PL3057586T3 (enExample)
PT (3) PT3057586T (enExample)
RS (3) RS60136B1 (enExample)
SA (1) SA516370965B1 (enExample)
SG (2) SG11201602996RA (enExample)
SI (3) SI3640241T1 (enExample)
SM (3) SMT202000273T1 (enExample)
TW (2) TWI676619B (enExample)
WO (1) WO2015058160A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189515B (zh) * 2013-03-14 2018-07-03 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的呋喃并吡啶类
BR112015022942B1 (pt) 2013-03-15 2022-02-22 Incyte Holdings Corporation Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
SMT202000273T1 (it) 2013-10-18 2020-07-08 Celgene Quanticel Research Inc Inibitori di bromodomini
EP3089970B1 (en) * 2013-12-09 2018-10-17 AbbVie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
NZ725930A (en) 2014-04-23 2023-04-28 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
EA036672B8 (ru) 2014-05-01 2021-01-13 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической деметилазы-1
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
WO2017024412A1 (en) 2015-08-12 2017-02-16 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
WO2017112703A1 (en) * 2015-12-24 2017-06-29 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
WO2017165139A1 (en) 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
HRP20200728T1 (hr) * 2016-04-15 2020-07-24 Abbvie Inc. Inhibitori bromodomene
JP2019513804A (ja) * 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3472157B1 (en) 2016-06-20 2023-04-12 Incyte Corporation Crystalline solid forms of a bet inhibitor
EP3474900A4 (en) * 2016-06-23 2020-03-11 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
CA3030581C (en) 2016-07-18 2021-05-25 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
JP7129973B2 (ja) * 2016-10-20 2022-09-02 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
PT3532059T (pt) * 2016-10-27 2022-03-02 Celgene Quanticel Res Inc Terapêutica de combinação de inibidores de proteínas de bromodomínio e domínio extraterminal
CN108069958A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
EP3600301B1 (en) 2017-03-30 2024-07-03 Albert-Ludwigs-Universität Freiburg Kdm4 inhibitors
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
US11192865B2 (en) * 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
CN110041333B (zh) 2018-01-16 2022-03-01 中国科学院上海药物研究所 溴结构域抑制剂化合物及其用途
CN112236172A (zh) 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
US20210261539A1 (en) * 2018-02-06 2021-08-26 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having bet inhibitory activity and preparation method and use therefor
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds
CA3107050A1 (en) 2018-07-23 2020-01-30 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
EP3846800A4 (en) * 2018-09-04 2022-08-24 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN109180579A (zh) * 2018-10-29 2019-01-11 四川大学 一种4-碘异喹啉酮的高效合成法
JP2022509534A (ja) * 2018-10-30 2022-01-20 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物
US12378240B2 (en) * 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
EP3917526A4 (en) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CN112174945B (zh) * 2019-07-02 2022-06-07 四川大学 具有抗癌作用的吲唑类化合物及其制备方法和用途
US11584756B2 (en) * 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
CN115052594B (zh) 2020-01-29 2024-07-16 福宏治疗公司 化合物和其用途
CN113264930B (zh) * 2020-02-17 2022-07-29 中国药科大学 吡咯类bet抑制剂及其制备方法与应用
CN113387879B (zh) * 2020-03-14 2023-05-30 成都先导药物开发股份有限公司 一种胺类衍生物、其制备方法及其在医药上的应用
WO2021222466A1 (en) * 2020-04-29 2021-11-04 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
MX2023002308A (es) 2020-08-25 2023-07-11 Lilly Co Eli Polimorfos de un inhibidor de ssao.
EP4288430A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117136057A (zh) 2021-02-22 2023-11-28 赛尔基因昆蒂赛尔研究公司 用于治疗前列腺癌的溴结构域(bet)抑制剂
CN115232131A (zh) * 2021-04-23 2022-10-25 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
CA3237514A1 (en) 2021-11-10 2023-05-19 Ellen Filvaroff Methods of treating glioblastoma
CN116135858B (zh) * 2021-11-16 2025-04-01 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
CN114316261B (zh) * 2022-01-09 2023-05-26 广西大学 一种三嗪框架多相催化剂及其制备方法与应用
WO2023141522A2 (en) * 2022-01-21 2023-07-27 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
WO2024238871A1 (en) * 2023-05-18 2024-11-21 Rectify Pharmaceuticals, Inc. Aryl sulfonamide compounds and their use in treating medical conditions
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
CN117886750A (zh) * 2023-11-20 2024-04-16 山东大学 一种具有brd4蛋白抑制作用的氮杂菲类化合物及其制备方法与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097613A1 (en) * 2002-05-16 2003-11-27 Almirall Prodesfarma Sa Pyridazin-3(2h)-one derivatives as pde4 inhibitors
JP2004143134A (ja) * 2002-02-13 2004-05-20 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
WO2004058729A1 (en) * 2002-12-26 2004-07-15 Almirall Prodesfarma Sa New pyridazin-3(2h)-one derivatives
EP1484320A1 (en) * 2002-02-13 2004-12-08 Takeda Chemical Industries, Ltd. Jnk inhibitor
US20070213323A1 (en) * 2004-09-17 2007-09-13 Imogai Hassan J Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
US20100256698A1 (en) * 2003-09-23 2010-10-07 Merck & Co., Inc. Isoquinolinone Potassium Channel Inhibitors
WO2011054848A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013097601A1 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Bromodomain inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2011970A1 (en) 1970-03-13 1971-11-18 CH. Boehringer Sohn, 6507 Ingelheim Imidazo-(1, 2-a)- pyrimidines prepn
US3635667A (en) 1970-07-23 1972-01-18 Fmc Corp Drycleaning with hydrogen peroxide
BE786028A (fr) 1971-07-08 1973-01-08 Boehringer Sohn Ingelheim 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer
DE2356005A1 (de) 1973-11-09 1975-05-22 Boehringer Sohn Ingelheim Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung
AU577105B2 (en) 1985-04-02 1988-09-15 T.P.O. :Pharmachim: Acylaminic penicillin derivatives
US5466697A (en) * 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
CA2495338A1 (en) 2002-09-26 2004-04-08 Pfizer Inc. Pyrazole amides for treating hiv infections
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
KR100703068B1 (ko) 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CA2562126A1 (en) 2004-04-01 2005-10-13 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
KR100781704B1 (ko) 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
ATE521595T1 (de) 2005-07-26 2011-09-15 Sanofi Sa Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
US20070099911A1 (en) 2005-10-28 2007-05-03 Wyeth Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
KR101474228B1 (ko) 2006-12-27 2014-12-18 사노피 사이클로알킬아민 치환된 이소퀴놀론 유도체
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
WO2008103277A2 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CN104447716A (zh) * 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
EP2426109B1 (en) * 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
MX2010008375A (es) 2008-01-30 2011-03-04 Cephalon Inc Star Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
WO2009158396A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
BRPI0924059A2 (pt) * 2008-12-23 2015-07-07 Hoffmann La Roche Didro piridona amidas como moduladores de p2x7
JP5485391B2 (ja) 2009-07-30 2014-05-07 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７調節薬としてのジヒドロピリミドンアミド類
EP2280088A1 (de) 2009-07-31 2011-02-02 Siemens Aktiengesellschaft Vorrichtung zum Kippen eines metallurgischen Schmelzgefäßes, metallurgische Schmelzanordnung und Verfahren unter Verwendung einer solchen Schmelzanordnung
IL295518B2 (en) 2009-10-06 2023-11-01 Millennium Pharm Inc Heterocyclic compounds useful as pdk1 inhibitors
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2792799T3 (es) 2010-06-28 2020-11-12 Merck Patent Gmbh [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013064984A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
CN103183675A (zh) 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
BR112014031068A2 (pt) * 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN105189515B (zh) 2013-03-14 2018-07-03 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的呋喃并吡啶类
WO2014169843A1 (en) * 2013-04-18 2014-10-23 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
KR20160012194A (ko) 2013-05-27 2016-02-02 노파르티스 아게 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP6403761B2 (ja) 2013-05-28 2018-10-10 ノバルティス アーゲー ピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
HK1224297A1 (zh) 2013-06-28 2017-08-18 Abbvie Inc. 布罗莫结构域抑制剂
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
SMT202000273T1 (it) 2013-10-18 2020-07-08 Celgene Quanticel Research Inc Inibitori di bromodomini
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004143134A (ja) * 2002-02-13 2004-05-20 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
EP1484320A1 (en) * 2002-02-13 2004-12-08 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2003097613A1 (en) * 2002-05-16 2003-11-27 Almirall Prodesfarma Sa Pyridazin-3(2h)-one derivatives as pde4 inhibitors
WO2004058729A1 (en) * 2002-12-26 2004-07-15 Almirall Prodesfarma Sa New pyridazin-3(2h)-one derivatives
US20100256698A1 (en) * 2003-09-23 2010-10-07 Merck & Co., Inc. Isoquinolinone Potassium Channel Inhibitors
US20070213323A1 (en) * 2004-09-17 2007-09-13 Imogai Hassan J Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2011054848A1 (en) * 2009-11-05 2011-05-12 Glaxosmithkline Llc Thetrahydroquinolines derivatives as bromodomain inhibitors
US20120208814A1 (en) * 2009-11-05 2012-08-16 Emmanuel Hubert Demont Thetrahydroquinolines Derivatives As Bromodomain Inhibitors
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013097601A1 (en) * 2011-12-30 2013-07-04 Abbvie Inc. Bromodomain inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gentile et al, Bioorganic & Medicinal Chemistry Letters (2011), 21(16), pages 4823-4827. *

Also Published As

Publication number Publication date
JP2019023192A (ja) 2019-02-14
PT3640241T (pt) 2022-11-21
TW202026282A (zh) 2020-07-16
US20180273547A1 (en) 2018-09-27
DK3640241T3 (da) 2022-11-28
CL2016000925A1 (es) 2017-02-03
US20200148703A1 (en) 2020-05-14
EP4134364A2 (en) 2023-02-15
SMT202000273T1 (it) 2020-07-08
US20240182490A1 (en) 2024-06-06
JP6445574B2 (ja) 2018-12-26
EP3057586A1 (en) 2016-08-24
US20150183784A1 (en) 2015-07-02
CA2927567A1 (en) 2015-04-23
LT3640241T (lt) 2022-12-27
SG10201804471PA (en) 2018-07-30
TW201605799A (zh) 2016-02-16
PL3290407T3 (pl) 2020-09-07
HRP20221389T1 (hr) 2023-01-06
PH12016500722A1 (en) 2016-05-30
CN105828820B (zh) 2020-01-07
MX371386B (es) 2020-01-27
NI201600056A (es) 2016-10-11
CY1122734T1 (el) 2021-05-05
DK3057586T3 (da) 2020-03-09
BR112016008593B1 (pt) 2022-10-18
EP3640241B1 (en) 2022-09-28
AU2014337064A1 (en) 2016-05-05
US20170158709A1 (en) 2017-06-08
CR20160229A (es) 2016-10-11
KR20160101899A (ko) 2016-08-26
PT3057586T (pt) 2020-03-13
FI3640241T3 (fi) 2023-01-13
TWI676619B (zh) 2019-11-11
EA201690734A1 (ru) 2016-10-31
US10023592B2 (en) 2018-07-17
US20150111885A1 (en) 2015-04-23
SI3057586T1 (sl) 2020-04-30
ES2775217T3 (es) 2020-07-24
PE20180248A1 (es) 2018-02-02
CA3148196A1 (en) 2015-04-23
PL3057586T3 (pl) 2020-05-18
LT3290407T (lt) 2020-04-10
US20220315601A1 (en) 2022-10-06
SI3640241T1 (sl) 2023-01-31
RS60136B1 (sr) 2020-05-29
KR102311573B1 (ko) 2021-10-12
EP3290407B1 (en) 2020-01-01
CN108558889A (zh) 2018-09-21
CL2018000318A1 (es) 2018-07-13
HRP20200341T1 (hr) 2020-06-12
SI3290407T1 (sl) 2020-07-31
US10562915B2 (en) 2020-02-18
SMT202200492T1 (it) 2023-01-13
CA2927567C (en) 2022-04-26
LT3057586T (lt) 2020-03-10
PE20161065A1 (es) 2016-11-19
ES2930305T3 (es) 2022-12-09
IL245074B (en) 2019-02-28
SMT202000262T1 (it) 2020-07-08
IL256946B (en) 2019-02-28
CN105828820A (zh) 2016-08-03
US9598372B2 (en) 2017-03-21
HRP20200492T1 (hr) 2020-06-26
US20160115134A1 (en) 2016-04-28
AU2019201352B2 (en) 2020-08-20
RS60002B1 (sr) 2020-04-30
IL245074A0 (en) 2016-06-30
AU2019201352A1 (en) 2019-03-21
EP3290407A1 (en) 2018-03-07
ES2774318T3 (es) 2020-07-20
CN108558889B (zh) 2021-11-05
PT3290407T (pt) 2020-04-06
EP4134364A3 (en) 2023-06-14
HUE060767T2 (hu) 2023-04-28
WO2015058160A1 (en) 2015-04-23
TWI771630B (zh) 2022-07-21
HUE048371T2 (hu) 2020-07-28
US11884680B2 (en) 2024-01-30
NZ718981A (en) 2021-03-26
SA516370965B1 (ar) 2020-08-05
EA035727B1 (ru) 2020-07-31
US9034900B2 (en) 2015-05-19
BR112016008593A8 (pt) 2020-03-10
MX393993B (es) 2025-03-24
MX2016005038A (es) 2016-09-13
JP2016533397A (ja) 2016-10-27
EP3640241A1 (en) 2020-04-22
PL3640241T3 (pl) 2022-12-05
DK3290407T3 (da) 2020-03-23
EP4134364B1 (en) 2025-07-30
US10941160B2 (en) 2021-03-09
EP3057586B1 (en) 2019-12-04
SG11201602996RA (en) 2016-05-30
EP3057586A4 (en) 2017-06-14
US9115114B2 (en) 2015-08-25
RS63733B1 (sr) 2022-12-30
JP6734896B2 (ja) 2020-08-05
CY1122886T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
AU2014337064B2 (en) Bromodomain inhibitors
HK40080347A (en) Bromodomain inhibitors
EA038715B1 (ru) Ингибиторы бромодомена
HK40017640A (en) Bromodomain inhibitors
HK40017640B (en) Bromodomain inhibitors
HK1226316B (en) Bromodomain inhibitors
HK1226316A1 (en) Bromodomain inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)